Description
OURXIME-O is a multi-antibiotic tablet containing Cefixime 200 mg and Ofloxacin 200 mg. The medication is prepared and sold by Pharvax Biosciences, which operates through its Medivaxia Pharma brand name. Ourxime-O is a clinically validated fixed-dose combination that combines third-generation oral cephalosporin (Cefixime) and second-generation fluoroquinolone (Ofloxacin), which are antibiotics with different non-overlapping bactericidal mechanisms to give better coverage against a broad spectrum of gram-positive, gram-negative, and atypical microorganisms causing bacterial infections.
The OURXIME-O antibiotic is especially good at treating cases of polymicrobial infections, where several bacteria cause infection concurrently. In such cases, where there may be more than one bacterium contributing to the infection, the antibiotic spectrum of Cefixime and Ofloxacin covers almost all the clinically significant bacteria in diseases like urinary tract infections, respiratory tract infections, enteric fever, and sexually transmitted infections. OURXIME-O is a popular antibiotic combination available from the PCD Pharma Franchise of Pharvax Biosciences, packed in a 10 x 10 blister pack format.
Uses and Indications for Cefixime 200 mg + Ofloxacin 200 mg Tablets
Ourxime-O Tablets are recommended by doctors, urologists and general practitioners for the treatment of the following conditions:
- Urinary tract infections (UTIs): Uncomplicated and complicated UTIs due to E. coli, Klebsiella pneumoniae, Proteus mirabilis and other susceptible Gram-negative bacteria; this is the most commonly prescribed use for this combination of antibiotics
- Enteric fever (typhoid and paratyphoid fever): Due to Salmonella typhi and Salmonella paratyphi, respectively; the double coverage ensures bactericidal synergy against these Salmonella strains
- Lower respiratory tract infections: Community-acquired pneumonia, acute exacerbations of chronic bronchitis, and lower respiratory infections due to H. influenzae, S. pneumoniae and Moraxella catarrhalis
- Upper respiratory tract infections: Acute sinusitis and tonsillopharyngitis when infection involves gram-negative organisms
- Sexually transmitted infections (STIs): Uncomplicated gonorrhea caused by Neisseria gonorrhoeae; additionally, Ofloxacin offers cover against Chlamydia trachomatis, a frequently coexisting infection
- Skin and soft-tissue infections: Due to gram-positive and gram-negative organisms susceptible to this drug combination
- Gastrointestinal infections: Bacterial gastroenteritis and travellers’ diarrhoea due to E. coli, Shigella, Salmonella, and Campylobacter species
- Pelvic inflammatory disease (PID): Used as part of antibiotic combinations in the treatment of upper genital tract infections in women
How Cefixime 200 mg + Ofloxacin 200 mg Tablets Works
OURXIME-O delivers dual-mechanism bactericidal action through two completely distinct and non-overlapping pathways — making cross-resistance virtually impossible and the spectrum of antibacterial coverage far broader than either agent alone.
Cefixime 200 mg is a third-generation oral cephalosporin that acts against the synthesis of bacterial cell walls by binding to the penicillin-binding proteins (PBPs), especially PBP3, of the bacterial cell membrane, thus interfering with the cross-linking process of peptidoglycan strands in the cell wall of bacteria. Cefixime causes the gradual disintegration of the cell walls of bacteria, causing instability of the bacterial cell and ultimately leading to bacterial lysis. It is very stable against hydrolysis by several plasmid-mediated beta-lactamases and thus works effectively on beta-lactamase-producing Gram-negative bacteria such as H. influenzae, M. catarrhalis, and several strains of E. coli.
Ofloxacin 200 mg is a fluoroquinolone that is capable of demonstrating bactericidal effects through inhibition of two topoisomerases in the bacteria, namely, DNA gyrase (topoisomerase II) and topoisomerase IV. Topoisomerases regulate the processes of supercoiling, relaxing, and strand separation of bacterial DNA during the replication and transcription processes. With the inhibition of topoisomerases, Ofloxacin traps topoisomerases in a DNA-enzyme complex, resulting in the creation of double-strand DNA breaks, blocking bacterial DNA replication, and leading to a quick death of bacterial cells. The spectrum of action of Ofloxacin involves gram-positive cocci, gram-negative bacteria (Pseudomonas aeruginosa), atypical organisms (Chlamydia, Mycoplasma, Legionella) and intracellular organisms, which cannot be provided with Cefixime.
Dosage and Administration
OURXIME-O Tablets are for oral use only. Take with or after food — particularly important for Cefixime, whose bioavailability is improved by food intake, and to minimise Ofloxacin-related gastric irritation. The dose, frequency, and duration of therapy are strictly as prescribed by a registered medical practitioner based on the type and severity of infection, the patient’s age, weight, and renal function. Always complete the full prescribed antibiotic course even if symptoms resolve earlier — incomplete antibiotic courses are the primary driver of antibiotic resistance. Swallow the tablet whole with a glass of water.
Side Effects of Cefixime 200 mg + Ofloxacin 200 mg Tablets
OURXIME-O is generally well tolerated if taken as per instructions. Side effects reported for both drugs may be:
- Nausea, vomiting, or gastric discomfort – The most frequent side effects; considerably decreased by ingestion with food.
- Diarrhoea or watery stools – A frequent occurrence in all broad-spectrum antibiotics; usually mild and transient.
- Headache or dizziness
- Rash or urticaria or pruritus
- Photosensitivity – Ofloxacin-induced increased sensitivity to sun rays; avoid sun exposure while taking the drug.
- Infrequently, tendinitis or rupture of tendons – Fluoroquinolone-induced adverse effect; chances are more in elderly people, individuals taking corticosteroids, or transplant recipients.
- Infrequently, prolongation of QTc interval – Ofloxacin-induced cardiovascular adverse effect; significant for individuals having pre-existing cardiac disorder or other drugs prolonging the QT interval.
- Infrequently, C. difficile-associated diarrhoea (CDAD); persistent or bloody diarrhoea needs to be reviewed by a physician.
- Infrequently, hypersensitivity reaction including anaphylaxis – Chances are more in individuals having a history of penicillin or cephalosporin allergy.
Precautions and Warnings for Cefixime 200 mg + Ofloxacin 200 mg Tablets
- Take with food to increase Cefixime availability and reduce gastric irritation caused by Ofloxacin.
- Avoid direct sunlight or UV light during the therapy – Ofloxacin increases the risk of photosensitivity reactions – wear protective clothing when sun exposure is inevitable.
- Avoid taking Ofloxacin simultaneously with antacids which contain aluminium, magnesium, or calcium or zinc and iron-containing drugs for at least 2 hours -Ofloxacin absorption is drastically reduced
- Alert the physician about allergies to cephalosporins, penicillin, or fluoroquinolones
- Use with caution in case of previous seizures or CNS disorders – fluoroquinolones may decrease the seizure threshold
- Not recommended for use in children younger than 12 years – fluoroquinolones should not be prescribed to children as they may have an adverse effect on developing cartilage
- Inform the physician about any other concurrent medication – significant drug interactions with warfarin (increases the effect of warfarin), theophylline (increased theophylline levels), antidiabetics and NSAIDs (increase the central nervous system side effects)
- Renal function test should be conducted prior to the start of therapy in older patients or in case of suspected kidney damage – dose adjustment for both ingredients may be required
- Should not be used in pregnant and breastfeeding women
Contraindications
OURXIME-O is contraindicated in patients with known hypersensitivity to Cefixime, Ofloxacin, other cephalosporins, fluoroquinolones, or any component of the formulation. It is contraindicated in children below 12 years of age (unless specifically directed by a paediatrician), in patients with a known history of tendinopathy related to fluoroquinolones, and in those with significant QTc prolongation. Use with extreme caution or avoid in patients with known penicillin allergy (cross-reactivity risk with Cefixime).
PCD Pharma Franchise for Cefixime 200 mg + Ofloxacin 200 mg Tablets
Pharvax Biosciences is a complete pharmaceutical company having more than 250 medicines in various therapeutic groups such as Medivaxia Pharma (General Antibiotic and Hospital Group), Gynaecology, Neuro & Pain and Paediatrics. We request all Pharma experts, Medical Representatives and Distributors across India to associate with us for PCD Pharma Franchise and Monopoly Distribution of OURXIME-O and the entire Medivaxia Antibiotic group.
The combination of Cefixime + Ofloxacin is one of the most extensively prescribed antibiotic combinations in India, especially in the UTI, Enteric Fever and Respiratory Infection category, making OURXIME-O a fast-moving medicine.
Disclaimer: OURXIME-O is a Schedule H prescription-only medicine. Use strictly under the supervision of a registered medical practitioner or physician. This document is for informational and PCD Pharma Franchise marketing purposes only and does not constitute medical advice.




